Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
CGCarlos G. Santos‐GallegoJAJuan Antonio Requena-IbáñezRSRodolfo San AntonioKIKiyotake IshikawaSWShin Watanabe
Icahn School of Medicine at Mount Sinai · Mount Sinai Hospital · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
651
total citations
- FWCI
- 53.24
- Percentile
- 100%
- References
- 41
Citations per year
Authors
12- CGCarlos G. Santos‐GallegoCorresponding
Icahn School of Medicine at Mount Sinai
- JAJuan Antonio Requena-Ibáñez
Mount Sinai Hospital, Hospital General Universitario de Ciudad Real, Icahn School of Medicine at Mount Sinai
- RSRodolfo San Antonio
Mount Sinai Hospital, Hospital Clínic de Barcelona, Icahn School of Medicine at Mount Sinai
- KIKiyotake Ishikawa
Cardiovascular Institute of the South, Icahn School of Medicine at Mount Sinai
- SWShin Watanabe
Cardiovascular Institute of the South, Icahn School of Medicine at Mount Sinai
Topics & keywords
Topics
Keywords
- Empagliflozin
- Medicine
- Cardiology
- Internal medicine
- Myocardial infarction
- Ejection fraction
- Heart failure
- Ketone bodies
No related works found for this paper.